Measuring altered disposition of xenobiotics in experimental models of liver disease

Current Protocols in Toxicology

Volumn 1, Issue SUPPL.52, 2012, Pages

  Hardwick, Rhiannon N ^a   Cherrington, Nathan J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Drug disposition; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Steatosis

Indexed keywords

DRUG; XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CATHETERIZATION; ARTICLE; BILE; BLOOD SAMPLING; CHRONIC LIVER DISEASE; COMMON BILE DUCT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG URINE LEVEL; FATTY LIVER; FEMORAL ARTERY; FEMORAL VEIN; LIVER FUNCTION TEST; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; VEIN CATHETERIZATION; XENOBIOTIC METABOLISM; ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; METABOLIC CLEARANCE RATE; METABOLISM; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ANIMALS; BILE; DISEASE MODELS, ANIMAL; FATTY LIVER; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C57BL; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; XENOBIOTICS;

EID: 84865640622     PISSN: 19349254     EISSN: 19349262     Source Type: Journal    
DOI: 10.1002/0471140856.tx2301s52     Document Type: Article

References (31)

1. Adams, L.A. and Angulo, P. 2005. Recent concepts in non-alcoholic fatty liver disease. Diab. Med. 22:1129-1133.
2. Ali, R. and Cusi, K. 2009. Newdiagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann. Med. 41:265-278.
3. Angulo, P. 2002. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346:1221-1231.
4. Arsov, T., Larter, C.Z., Nolan, C.J., Petrovsky, N., Goodnow, C.C., Teoh, N.C., Yeh, M.M., and Farrell, G.C. 2006a. Adaptive failure to highfat diet characterizes steatohepatitis in Alms1 mutant mice. Biochem. Biophys. Res. Comm. 342:1152-1159.
5. Arsov, T., Silva, D.G., O'Bryan, M.K., Sainsbury, A., Lee, N.J., Kennedy, C., Manji, S.S.M., Nelms, K., Liu, C., Vinuesa, C.G., de Kretser, D.M., Goodnow, C.C., and Petrovsky, N. 2006b. Fat Aussie-A New Alström Syndrome mouse showing a critical role for ALMS1 in obesity, diabetes, and spermatogenesis. Mol. Endocrinol. 20:1610-1622.
6. Barr, J., Vázquez-Chantada, M., Alonso, C., Pérez-Cormenzana, M., Mayo, R., Galán, A., Caballería, J., Martín-Duce, A., Tran, A., Wagner, C., Luka, Z., Lu, S.C., Castro, A., Le Marchand-Brustel, Y., Martínez-Chantar, M.L., Veyrie, N., Clément, K., Tordjman, J., Gaul, P., andMato, J.M. 2010. Liquid chromatographymass-spectrometry-based parallel profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J. Proteome Res. 9:4501-4512.
7. Byrne, C.D., Olufadi, R., Bruce, K.D., Cagampang, F.R., and Ahmed, M.H. 2009. Metabolic disturbances in non-alcoholic fatty liver disease. Clin. Sci. 116:539-564.
8. Carmiel-Haggai, M., Cederbaum, A.I., and Neito, N. 2005. A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. FASEB J. 19:136-138.
9. Cheung, O. and Sanyal, A.J. 2009. Recent advances in nonalcoholic fatty liver disease. Curr. Opin. Gastroenterol. 25:230-237.
10. Day, C.P. 2002. Pathogenesis of steatohepatitis. Best Pract. Res. Clin. Gastroenterol. 16:663-678.
11. Donovan, J. and Brown, P. 2006. Euthanasia. Curr. Protoc. Immunol. 73:1.8.1-1.8.4.
12. Fan, J.G. 2008. Impact of non-alcoholic fatty liver disease on accelerated metabolic complications. J. Digest. Dis. 9:63-67.
13. Fan, J.G. and Qiao, L. 2009. Commonly used animal models of non-alcoholic steatohepatitis. Hepatobiliary Pancreat. Dis. Int. 8:233-240.
14. Fisher, C.D., Lickteig, A.J., Augustine, L.M., Oude Elferink, R.P.J., Besselsen, D.G., Erickson, R.P., and Cherrington, N.J. 2009. Experimental nonalcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur. J. Pharmacol. 613:119-127.
15. Hanley, M.J., Abernethy, D.R., and Greenblatt, D.J. 2010. Effect of obesity on the pharmacokinetics of drugs in humans. Clin. Pharmacokinetics 49:71-87.
16. Jow, J., Choi, S.S., and Diehl, A.M. 2008. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin. Liver Dis. 28:370-379.
17. Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., Ferrell, L.D., Liu, Y., Torbenson, M.S., Unalp-Arida, A., Yeh, M., McCullough, A.J., and Sanyal, A.J. 2005. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321.
18. Koteish, A. and Mae Diehl, A. 2002. Animal models of steatohepatitis. Best Pract. Res. Clin. Gastroenterol. 16:679-690.
19. Lall, C.G., Aisen, A.M., Bansal, N., and Sandrasegaran, K. 2008. Nonalcoholic fatty liver disease. Am. J. Roentgenol. 190:993-1002.
20. Larter, C.Z. and Yeh, M.M. 2008. Animal models of NASH: Getting both pathology and metabolic contaxt right. J. Gastroenterol. Hepatol. 23:1635-1648.
21. Larter, C.Z., Yeh, M.M., Van Rooyen, D.M., Teoh, N.C., Brooling, J., Hou, J.Y., Williams, J., Clyne, M., Nolan, C.J., and Farrell, G.C. 2009. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice. J. Gastroenterol. Hepatol. 24:1658-1668.
22. Lickteig, A.J., Fisher, C.D., Augustine, L.M., Aleksunes, L.M., Besselsen, D.G., Slitt, A.L., Manautou, J.E., and Cherrington, N.J. 2007. Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab. Dispos. 35:1970-1978.
23. Malone, M. 2003. Altered drug disposition in obesity and after bariatric surgery. Nutr. Clin. Pract. 18:131-135.
24. Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, N., Melchionda, N., and Rizzetto, M. 2003 Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917-923.
25. Marra, F., Gastaldelli, A., Baroni, G.S., Tell, G., and Tiribelli, C. 2008. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol. Med. 14:72-81.
26. Mattar, S.G., Valcu, L.M., Rabinovitz, M., Demetris, A.J., Krasinskas, A.M., Barinas-Mitchell, E., Eid, G.M., Ramanathan, R., Taylor, D.S., and Schauer, P.R. 2005. Surgicallyinduced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann. Surg. 242:610-620.
27. McCullough, A.J. 2006. Pathophysiology of nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 40:S17-S29.
28. Schattenberg, J.M. and Gale, P.R. 2010. Animal models of non-alcoholic steatohepatitis:Ofmice and man. Digestive Dis. 28:247-254.
29. Tilg, H. and Moschen, A.R. 2010. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 52:1836-1846.
30. Varela-Rey, M., Embade, N., Ariz, U., Lu, S.C., Mato, J.M., and Martinez-Chantar, M.L. 2009. Non-alcoholic steatohepatitis and animal models: Understanding the human disease. Int. J. Biochem. Cell Biol. 41:969-976.
31. Zahra, F. and Kleiner, D.E. 2011. Update on fatty liver disease and steatohepatitis. Adv. Anatom. Pathol. 18:294-300.